NairobiDemand for injectable HIV prevention has outrun supply in early-adopting countries, health charities warned.
Charities reported depleted stocks and unequal access as rollout of the long-acting shot expanded.
The shortage is concentrating doses in better-resourced facilities.
Sources: SciDev.Net
WHAT THE SHOT DOES
Long-acting injectable pre-exposure prophylaxis (PrEP) replaces a daily pill with an intramuscular dose given every two months (cabotegravir) or every six months (lenacapavir). Adherence — the single biggest failure point of daily PrEP in real-world cohorts — becomes a calendar problem instead of a willpower problem.
WHY THE BOTTLENECK IS PRICE, NOT CHEMISTRY
Lenacapavir costs roughly $42,000 per person per year at US list price. Generics manufacturers in India have shown they can make the same molecule for under $40 per year at scale. The gap between those two numbers is patent enforcement, not manufacturing difficulty.
THE LICENSING THROTTLE
Voluntary licenses from originators to generics manufacturers carve the world into 'included' and 'excluded' countries. Middle-income states with significant HIV burden — Brazil, much of Latin America, parts of Eastern Europe — are routinely excluded from the cheap-generic geography even when their epidemics are severe.
WHO GETS DOSED FIRST
When supply is scarce, doses concentrate where cold chain, trained injectors, and laboratory follow-up already exist — urban academic hospitals, donor-funded demonstration sites. Rural clinics and key-population programs (sex workers, men who have sex with men, people who inject drugs) get rationed out, which inverts the epidemiological logic of targeting highest-incidence groups.
THE AIDS PRECEDENT
This is the second time the same fight has played out. From 1996 to 2003, antiretroviral therapy existed but cost ~$10,000 per year, while 25 million Africans died waiting. Indian generics, Brazilian compulsory licensing threats, and the Doha Declaration eventually broke the price. The current injectable shortage is a faster replay of the same structural problem.
WHY A SHORTAGE IS WORSE THAN NO ROLLOUT
Interrupted injectable PrEP carries a specific risk: the drug clears slowly, so someone who misses a dose has weeks of sub-therapeutic drug exposure. If they acquire HIV during that tail, the resulting infection can be resistant to the same drug class. A stockout doesn't just stop prevention — it can seed resistant virus into the epidemic.